AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 3.64% on an annualized basis producing an average annual return of 15.04%. Currently, AbbVie has a market capitalization of $250.56 billion.
August 11, 3:11 PM
Chardan initiated coverage on Oyster Point Pharma Inc (NASDAQ:OYST) with a Buy rating and a price target of $22. The lead product,…
August 9, 1:38 PM
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
August 3, 2:23 PM
As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their stock.
August 3, 8:52 AM
Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the U.S. FDA approval of JUVÉDERM® VOLUX™ XC for the improvement of jawline definition in adults over the age of 21 with
August 2, 6:32 AM
Sosei Group Corporation and AbbVie Inc (NYSE:ABBV) announced a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules…
Sosei Heptares and AbbVie Announced New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases; Sosei Heptares Eligible to Receive up to $80M in Upfront, Near-term Milestone Payments; Up to $1….
August 1, 7:18 PM
Sosei Group Corporation ("the Company"; TSE: 4565) and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announce they have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR)